<div id="content" class="col-md-12" style="">
<div data-drupal-messages-fallback="" class="hidden"/><div id="block-medsites-page-title" class="widget block">
<h1><span property="schema:name">Upper GI Bleed in Cirrhosis</span>
</h1>
</div>
<div id="block-medsites-content" class="widget block">
<article data-history-node-id="943" role="article" about="/commodorecompendium/upper-gi-bleed-cirrhosis" typeof="schema:WebPage">
<div>
<div property="schema:text" class="field field--name-body field--type-text-with-summary field--label-hidden field__item"><div class="WordSection1">
<div style="border-bottom:solid windowtext 1.0pt; border-top:double windowtext 1.5pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
<p style="border:none; padding:0in"><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Gastroesophageal Varices and Hemorrhage – Patricia Checinski</span></span></b></span></span></span></span></p>
</div>
<p><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Background</span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Form due to portosystemic collaterals and enlarge in the setting of portal HTN, typically through the coronary and/or short gastric veins</span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Mechanistically: intrahepatic resistance to portal flow from regenerative nodules and fibrosis, as well as </span></span><span style="font-size:12.0pt"><span style="font-family:&quot;Wingdings 3&quot;">#</span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> intrahepatic vascular tone due to endothelial dysfunction</span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Variceal hemorrhage is the cause of ~ 70% of UGIB in pts with portal HTN</span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">The risk of mortality with each episode of esophageal variceal hemorrhage (EVH) is 15-25%. Recurrence occurs in 60% of patients within 1-2 years of the index event</span></span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Variceal Screening: </span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Not all pts with cirrhosis require screening. Can be omitted with low liver stiffness (on elastography) and with platelets &gt;150; otherwise screening is necessary.</span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Compensated cirrhosis w/o varices </span></span><span style="font-size:12.0pt"><span style="font-family:Wingdings"></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> EGD q3yr, unless active liver injury (obesity, EtOH use, ongoing viral infxn), then q2yr</span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Compensated cirrhosis w/small varices </span></span><span style="font-size:12.0pt"><span style="font-family:Wingdings"></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> EGD q2yr unless active liver injury, then q1yr</span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Decompensated cirrhosis with no or small nonbleeding varices</span></span><span style="font-size:12.0pt"><span style="font-family:Wingdings"></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> EGD q1yr, and at initial time of decompensation</span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">If these pts are on Non-selective </span></span><span style="font-size:12.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif">β</span></span><span style="font-size:12.0pt"><span style="font-family:Palatino">-blocker (NSBB) for 1º ppx w/HR 55-60, no need to screen</span></span></span></span></span></span></li>
</ul>
<p> </p>
</div>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Management (Non-Bleeding Varices)</span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Indicated for medium to large varices or high-risk small varices (with red signs)</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Primary ppx with either NSBB (preferred) or endoscopic band ligation (EBL), not both </span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">NSBB: decrease hepatic venous pressure gradient (HVPG) and portal venous flow by decreasing cardiac output (</span></span><span style="font-size:12.0pt"><span style="font-family:&quot;Cambria&quot;,serif">β</span></span><span style="font-size:12.0pt"><span style="font-family:Palatino">1 blockade) and allowing unopposed alpha-adrenergic activity (</span></span><span style="font-size:12.0pt"><span style="font-family:&quot;Cambria&quot;,serif">β</span></span><span style="font-size:12.0pt"><span style="font-family:Palatino">2 blockade). Start NSBB such as nadolol (given nightly as portal pressures are highest at night) or propranolol (BID). Carvedilol has been shown to have a greater reduction in portal pressures and may be most preferred if tolerated.</span></span></span></span></span>
<ul>
<li style="list-style-type:none">
<ul style="list-style-type:circle">
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">For 2 º ppx, initiate ~72hr after acute bleed has resolved and octreotide discontinued</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Titrate dose to reduce resting HR by ~25% (or target HR 55-60)</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Ask pt to check their HR and BP 2-3 days after discharge or after clinic visit and contact provider for further titration</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Discontinue if: hypotension, AKI, SBP or hyponatremia (w/refractory ascites)</span></span></span></span></span></li>
</ul>
</li>
</ul>
</li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">EBL is performed in medium to large varices, any varices with red wale marks</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">For secondary ppx, pts should be on BB AND undergo EBL. BB are associated with reduced mortality, while EBL is not (EBL does not eradicate the HVPG)</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">TIPS should not be used for primary ppx</span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Management (Variceal Bleeding)</span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Assess severity: tachycardia suggests 10% volume loss, orthostatic hypotension 20% volume loss, shock 30% volume loss</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Place two large-bore IVs (18G or larger), resuscitate w/ blood products and albumin</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">If hypotensive, try MAC placement and activate massive transfusion protocol (MTP)</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Consider intubation if need for emergent EGD, change in mental status, ongoing hematemesis, concern of ability to protect airway</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Start octreotide 50 mcg IV bolus followed by continuous infusion of 50 mcg/h, to be continued for 3 days should EVH be confirmed on endoscopy</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Ceftriaxone 1g IV q24h for SBP prophylaxis (reduced mortality), then transition to PO ciprofloxacin for total 7-day course</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">IV protonix 40 mg BID (can dc after EGD if no ulcer)</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Consult GI or alert fellow for upper endoscopy. Endoscopic therapies performed include variceal band ligation and sclerotherapy. EBL is more effective than sclerotherapy to control bleeding, sclerotherapy is used when ligation is not feasible. Repeat endoscopy if re-bleeding occurs after initial successful therapy.</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Consider balloon tamponade with Blakemore as temporizing measure before definitive management. Patient must be intubated before placement, and preferably GI should be made aware prior to placement.</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">No role for the correction of INR, even in the presence of bleeding as excessive blood products and FFP can increase portal pressures and cause worsening bleeding</span></span></span></span></span>
<ul style="list-style-type:circle">
<li style="margin-right:12px"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Vitamin K can be given w/ </span></span><span style="font-size:12.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif">↑</span></span><span style="font-size:12.0pt"><span style="font-family:Palatino">  INR, though is unlikely to help in the acute setting</span></span></span></span></span></li>
<li style="margin-right:12px"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Check Fibrinogen and give cryo if fibrinogen is &lt;120 given its low volume</span></span></span></span></span></li>
<li style="margin-right:12px"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">AASLD does not recommend specific platelet targets during variceal hemorrhage</span></span></span></span></span></li>
<li style="margin-right:12px"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Administer blood products in balanced ratio to avoid transfusion related coagulopathy (VUMC MTP is 6:4:1 of RBC:FFP:PLT)</span></span></span></span></span></li>
</ul>
</li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Transjugular intrahepatic portosystemic shunt (TIPS) can be considered as a rescue therapy for rebleeding or refractory bleeding, or occasionally as preemptive therapy,</span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Order TTE early in course, as well as triple phase CT for pre-procedural planning. Duplex of portal and hepatic veins can be substituted in the setting of severe AKI</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">TIPS is relatively contraindicated in pts with elevated MELD, evidence of R heart dysfunction, and active or difficult to control hepatic encephalopathy</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">TIPS can be considered “preemptively” if bleeding was controlled in pts at high risk of failure or rebleeding (Child B 8-9 with active bleeding on prior endoscopy or Child C 10-13 regardless of endoscopy findings)</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">For gastric varices, endoscopic management can be attempted with EBL or sclerotherapy. TIPS should be considered early in pts with cardiofundal varices, though other interventional options are coiling via IR with BATO and BRT</span></span></span></span></span>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="vertical-align:baseline"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Recent data supports BRTO over glue injection for gastric varices</span></span></span></span></span></span></li>
</ul>
</li>
</ul>
</li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Following TIPS placement, there is no need for NSBB or EVL, as the TIPS has decompressed the portal system and should be considered definitive management.</span></span></span></span></span>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Recurrent bleeding should prompt investigation of the TIPS</span></span></span></span></span></li>
</ul>
</li>
</ul>
</div>
</div>
</article>
</div>
</div>